Docetaxel-induced acute myositis: a case report with review of literature

References

• Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting . J Clin Oncol. 1993;11(10):2010–20.
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN, et al. Phase II trial of docetaxel : a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13(12):2886–94.
   PubMed Web of Science ®Google Scholar
• Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229–39.
   PubMed Web of Science ®Google Scholar
• Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, Chiu L, Chow R, Wan BA, Pasetka M, et al. A prospective study of docetaxel-associated pain syndrome. Support Care Cancer. 2018;26(1):203–11.
   PubMed Web of Science ®Google Scholar
• Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol. 2010;17(4):42–7.
   PubMed Web of Science ®Google Scholar
• Fang Y-F, Wu Y-J, Kuo C-F, Luo S-F, Yu K-H. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016;35(8):1977–84.
   PubMed Web of Science ®Google Scholar
• Minisini AM, Pauletto G, Bergonzi P, Fasola G. Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat. 2007;105(2):133–8.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Yokoyama M, Nishiyama S, Hashiguchi M, Aihara S, Yasunaga M, Noguchi M, Iwasaka T. Pyomyositis associated with chemotherapy for endometrial cancer: a case report. World J Surg Oncol. 2013;11:45.
   PubMed Web of Science ®Google Scholar
• Singh P, Chan W, Blomfield P, Mcintosh R. Pyomyositis after chemotherapy for endometrial cancer. Int J Gynecol. 2010;20(7):1256–8.
   Google Scholar
• Sasaki H, Yano M, Kawano O, Hikosaka YU, Fujii Y. Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel : A case report. Oncol Lett. 2012;3(2):300–2.
   PubMed Web of Science ®Google Scholar
• Gidron A, Quadrini M, Dimov N, Argiris A. Malignant Thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia. Am J Clin Oncol. 2006;29(2):213–4.
   PubMed Web of Science ®Google Scholar
• Le Quintrec JS, Le Quintrec JL. Drug-induced myopathies. Baillieres Clin Rheumatol. 1991;5(1):21–38.
   PubMedGoogle Scholar
• Hilkens P, Pronk L, Verweij J, Vecht C, Putten V, Bent M. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75(3):417–22.
   PubMed Web of Science ®Google Scholar
• Tofthagen C, McAllister R, Visovsky C. Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol. 2013;4(4):204–15.
   PubMedGoogle Scholar
• Freilich R, Balmaceda C, Seidman A, Rubin M, DeAngelis L. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47(1):115–8.
   PubMed Web of Science ®Google Scholar
• Fardet L, Stoebner P-E, Bachelez H, Descamps V, Kerob D, Meunier L, Dandurand M, Morel P, Lebbe C. Treatment with taxanes of refractory or life-threatening kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer. 2006;106(8):1785–9.
   PubMed Web of Science ®Google Scholar
• Winkelmann RR, Yiannias JA, DiCaudo DJ, Trotter SC, Farhey Y, Griffing WL, Martorano LM, Winkelmann JC. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis. Int J Dermatol. 2016;55(1):97–100.
   PubMed Web of Science ®Google Scholar
• Rochigneux P, Schleinitz N, Ebbo M, Aymonier M, Pourroy B, Boissier R, Salas S, Deville J-L. Acute myositis: an unusual and severe side effect of docetaxel: a case report and literature review. Anticancer Drugs. 2018;29(5):477–81.
   PubMed Web of Science ®Google Scholar
• Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11(3):664.
   PubMed Web of Science ®Google Scholar
• Perel-Winkler A, Belokovskaya R, Amigues I, Larusso M, Hussain N. Case report a case of docetaxel induced myositis and review of the literature. Case Rep Rheumatol. 2015;2015:1–8.
   Google Scholar
• Ardavanis A, Ioannidis G, Rigatos G, Savas S, Hospital A-O. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res. 2005;15(1B):523–5.
   Google Scholar
• Hughes BGM, Stuart-Harris R. Docetaxel-induced myositis: report of a novel side-effect. Intern Med J. 2005;35(6):369–70.
   PubMed Web of Science ®Google Scholar
• Moran E, Mastaglia L. Cytokines in immune-mediated inflammatory myopathies : cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014;178(3):405–15.
   PubMed Web of Science ®Google Scholar
• Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14(5):255–68.
   PubMed Web of Science ®Google Scholar
• Figarella-Branger D, Civatte M, Bartoli C, Pellissier J-F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28(6):659–82.
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87(1):21–7.
   PubMed Web of Science ®Google Scholar
• Collins T, Lee L, Ting J. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother. 2000;49(2):78–84.
   PubMed Web of Science ®Google Scholar
• Lee L, Li G, Templeton D, Ting J. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 1998;273(43):28253–60.
   PubMed Web of Science ®Google Scholar
• White C, Martin B, Lee L, Haskill J, Ting J. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother. 1998;46(2):104–12.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94–102.
   PubMed Web of Science ®Google Scholar